Who is sponsoring NCT05455736?

NCT05455736 is sponsored by Azienda Ospedaliero-Universitaria Careggi.

What drugs are being tested in NCT05455736?

Interventions in NCT05455736: Stereotactic salvage radiotherapy for macroscopic prostate bed relapse.

What condition does NCT05455736 study?

NCT05455736 studies Prostate Cancer, Relapse.

Is NCT05455736 still recruiting?

NCT05455736 is currently status unknown. Last updated 13 July 2022.

Last reviewed 2022-07-13 · How we verify

NCT05455736: STARR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence After prostatectomy-a Prospective Observational Study

Status unknown Last updated 13 July 2022

What this trial tests

trial testing Stereotactic salvage radiotherapy for macroscopic prostate bed relapse in Prostate Cancer in 90 participants. Status unknown.

Timeline

11 March 2021

Primary endpoint
11 July 2023

11 July 2024

Quick facts

Lead sponsor	Azienda Ospedaliero-Universitaria Careggi
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	90
Start date	11 March 2021
Primary completion	11 July 2023
Estimated completion	11 July 2024
Sites	1 location across Italy

Drugs / interventions tested

Stereotactic salvage radiotherapy for macroscopic prostate bed relapse

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Relapse — all drugs for Relapse →

Sponsor

Azienda Ospedaliero-Universitaria Careggi — full company profile →

Who can join

18 and older, male only, with Prostate Cancer or Relapse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

STereotactic sAlvage Radiotherapy for macroscopic prostate bed Recurrence after prostatectomy (STARR trial) is a prospective observational study aimed to assess outcome after Stereotactic salvage radiotherapy (SSRT) for macroscopic prostate bed recurrence after radical prostatectomy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Three Months' PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy-STARR (NCT05455736).
Francolini G, Garlatti P, Di Cataldo V, Detti B, et al · · 2023 · cited 9× · PMID 36765948 · DOI 10.3390/cancers15030992
ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy.
Dirix P, Dal Pra A, Khoo V, Carrie C, et al · · 2023 · cited 1× · PMID 37808453 · DOI 10.1016/j.ctro.2023.100684
Stereotactic Salvage Radiotherapy for Macroscopic Prostate Bed Recurrence After Prostatectomy: STARR (NCT05455736): An Early Analysis from the STARR Trial.
Bertini N, Francolini G, Di Cataldo V, Garlatti P, et al · · 2025 · PMID 40647393 · DOI 10.3390/cancers17132092

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Azienda Ospedaliero-Universitaria Careggi trials

Trials by the same sponsor.

NCT07296055 — Endobronchial Valve in Tubercular and NTM Pulmonary Cavities. · NA · not yet recruiting
NCT07289581 — Effect of Treatment With Butyric Acid in Anorexia Nervosa · NA · active not recruiting
NCT06978608 — Ultrasound and Somatosensory Median Nerve Evaluation in CRPS I · not yet recruiting
NCT07005882 — Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Ra · Phase 2 · not yet recruiting
NCT06529601 — Comparison Between CAD/CAM and Conventional Mandibular Fixed Retainers. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05455736 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliero-Universitaria Careggi
Last refreshed: 13 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05455736.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing